Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial)

Jagdish Prasad Meena, Debasish Sahoo, Harshita Makkar, Sujata Bhattacharya, Aditya Kumar Gupta, Deepam Pushpam, Manisha Jana, Aanchal Kakkar, Bangkim Chandra Khangembam, Maroof Ahmad Khan, Narendra Kumar Chaudhary, Nidhi Chopra, Prashant Prabhakar, Amitabh Singh, Shilpa Khanna Arora, Nishant Verma, Sonali Mohapatra, Maharshi Trivedi, Parichay Singh, Vineeta Gupta, Pankaj Dwivedi, Sameer Bakhshi, Imteyaz Ahmad Khan, Lata Singh, Piali Mandal, Rachna Seth · 2026

Read Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial) by Jagdish Prasad Meena, Debasish Sahoo, Harshita Makkar, Sujata Bhattacharya, Aditya Kumar Gupta, Deepam Pushpam, Manisha Jana, Aanchal Kakkar, Bangkim Chandra Khangembam, Maroof Ahmad Khan, Narendra Kumar Chaudhary, Nidhi Chopra, Prashant Prabhakar, Amitabh Singh, Shilpa Khanna Arora, Nishant Verma, Sonali Mohapatra, Maharshi Trivedi, Parichay Singh, Vineeta Gupta, Pankaj Dwivedi, Sameer Bakhshi, Imteyaz Ahmad Khan, Lata Singh, Piali Mandal, Rachna Seth (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13534399.txt.

Description

Jagdish Prasad Meena and colleagues set out in 2026 a trial plan testing bevacizumab added to standard first-phase chemotherapy for children with high-risk neuroblastoma. The cancer is the most common solid tumour outside the brain in children, and long-term survival stays below half despite intense care. Response to first-phase drugs strongly predicts later survival.

Children will be assigned by chance to standard drugs alone or standard drugs plus bevacizumab, which blocks blood vessel growth. Responders move to stem cell transplant, and all children are followed for at least two years. Planned outcomes cover response rate, survival, toxicity, and leftover disease.

Catalog record

CREATORJagdish Prasad Meena, Debasish Sahoo, Harshita Makkar, Sujata Bhattacharya, Aditya Kumar Gupta, Deepam Pushpam, Manisha Jana, Aanchal Kakkar, Bangkim Chandra Khangembam, Maroof Ahmad Khan, Narendra Kumar Chaudhary, Nidhi Chopra, Prashant Prabhakar, Amitabh Singh, Shilpa Khanna Arora, Nishant Verma, Sonali Mohapatra, Maharshi Trivedi, Parichay Singh, Vineeta Gupta, Pankaj Dwivedi, Sameer Bakhshi, Imteyaz Ahmad Khan, Lata Singh, Piali Mandal, Rachna Seth
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44331
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13534399

Browse the full library · About the Tower of Babel